Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Nipro Tanabe Pharma, formerly known as Tanabe Seiyaku Hanbai, is a Japanese pharmaceutical company specializing in the manufacture and sale of generic drugs. Originally a subsidiary of Mitsubishi Tanabe Pharma, the company was acquired by Nipro Corporation in 2017 to strengthen Nipro's generic drug business. The company provides a wide range of high-quality generic medications across various therapeutic areas, including cardiovascular, gastrointestinal, and metabolic diseases. It leverages the manufacturing expertise of the Nipro Group to ensure a stable supply of essential medicines to the Japanese healthcare market. The company is headquartered in Osaka and operates as a key component of Nipro's domestic pharmaceutical strategy.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Tanabe Seiyaku Hanbai.